Article Text

Download PDFPDF

Correction: The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Rudwaleit M, van de Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann of Rheum Dis 2009;68:777–83. doi: 10.1136/ard.2009.108233

Conflicts of interest (competing interests) for this article were not provided in the paper. This correction now serves to provide conflict of interest statements of individual authors and of ASAS as an organisation with relevance to the years 2008/2009.

Conflicts of interest (in the order of authorship):

M Rudwaleit: speaking fees and/or consulting fees from Abbott, Centocor, MSD, Pfizer, Roche, Schering-Plough, Wyeth

D van der Heijde: research grants and/or consulting fees from Abbott, Amgen, BMS, Centocor, Chugai, Novartis, Pfizer, Schering-Plough, UCB and Wyeth.

R Landewé: research grants and/or consulting fees Abbott, Amgen/Immunex, Centocor, MSD (Merck), Shering-Plough, UCB, Wyeth

J Listing: no competing interests.

N Accoc: speaking fees and/or consultancies from Abbott, Wyeth, UCB, Schering and Novartis.

J Brandt: consultancy or speaking fees from Abbott, MSD, Pfizer, Roche.

J Braun: nothing declared

CT Chou: nothing declared

E Collantes-Estevez: research grants or consultation fees from Abbott, Schering Plough and Wyeth

M Dougados: research grants, speaking fees and consulting fees from Abbott, Janssen, Lilly, Merck, Novartis, Wyeth, UCB

F Huang: no competing interests.

J Gu: nothing declared.

MA Khan: consultancy and speaker fees from Amgen and Abbott.

Y Kirazli: research grants or consultation fees from Allergan, Amgen, Lilly, Novartis, Pfizer and Sandoz.

WP Maksymowych: fees for consulting, honoraria, and research grants from Abbott, Amgen-Wyeth, Schering-Plough.

H Mielants: no competing interests.

IJ Sørensen: lecture fees from Schering-Plough A/S, Wyeth and Abbott; consultancy fees from Bristol-Myers Squibb.

S Ozgocmen: no competing interests.

E Roussou: no competing interests.

R Valle-Oñate: no competing interests.

U Weber: no competing interests.

J Wei: research grants or consultation fee from Abbott, BMS, Chugai, Eisai, Wyeth.

J Sieper: honoraria for consultancies and/or being a member of speaker’s bureau from Abbott, Amgen, Centocor, Merck, Schering-Plough, Wyeth.

ASAS organisation: ASAS has received unrestricted grants for corporate membership from Abbott, Centocor, MSD, Pfizer, Schering-Plough, Wyeth.

View Abstract

Linked Articles